Quick Answer
Altimmune, Inc. reported Net Income Loss of -$88.09 million for the year ending 2025.
- Altimmune, Inc. showed an increase of +7.3% in Net Income Loss from 2024 to 2025.
- This data is from Altimmune, Inc.'s annual report (Form 10-K), filed with the SEC on March 6, 2026.
- XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2014: -$2.26 million | Q2 2014: -$439.1 thousand | Q3 2014: -$4.63 million | Q4 2014: -$2.63 million | Q1 2015: $1.46 million | Q2 2015: -$2.34 million | Q3 2015: -$1.32 million | Q4 2015: -$1.24 million | Q1 2016: -$1.23 million | Q2 2016: -$1.62 million | Q3 2016: -$4.80 million | Q4 2016: $77.80 million | Q1 2017: -$4.58 million | Q2 2017: -$3.11 million | Q3 2017: -$29.91 million | Q1 2018: -$3.17 million | Q2 2018: -$9.14 million | Q3 2018: -$2.35 million | Q1 2019: -$2.10 million | Q2 2019: -$3.39 million | Q3 2019: -$10.94 million | Q1 2020: -$3.89 million | Q2 2020: -$16.77 million | Q3 2020: -$17.77 million | Q1 2021: -$14.86 million | Q2 2021: -$24.83 million | Q3 2021: -$33.51 million | Q1 2022: -$19.43 million | Q2 2022: -$20.11 million | Q3 2022: -$23.52 million | Q1 2023: -$20.07 million | Q2 2023: -$16.06 million | Q3 2023: -$20.67 million | Q1 2024: -$24.39 million | Q2 2024: -$24.64 million | Q3 2024: -$22.85 million | Q1 2025: -$19.58 million | Q2 2025: -$22.15 million | Q3 2025: -$19.01 million.
- Over the full 16 years of available data (2010 to 2025), Altimmune, Inc.'s Net Income Loss has declined by 152.8%.
- Historical annual values: Fiscal year 2025: -$88.09 million | Fiscal year 2024: -$95.06 million | Fiscal year 2023: -$88.45 million | Fiscal year 2022: -$84.71 million | Fiscal year 2021: -$97.09 million | Fiscal year 2020: -$49.04 million | Fiscal year 2019: -$20.52 million | Fiscal year 2018: -$39.17 million | Fiscal year 2017: -$46.43 million | Fiscal year 2016: -$11.09 million | Fiscal year 2015: -$3.44 million | Fiscal year 2014: -$9.96 million | Fiscal year 2013: -$11.72 million | Fiscal year 2012: -$4.92 million | Fiscal year 2011: -$3.80 million | Fiscal year 2010: -$34.85 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: